Drug profile

The FDA adverse-event record for Recombitek C8 - 47K9.R0

206 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Recombitek C8 - 47K9.R0. See the species affected, top reactions, and outcomes below.

206
adverse-event reports
9.2%
death-coded share
Dog
most-reported species
49
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
206
Total Reports
19
Deaths Reported
9.2%
Death Rate

Active Ingredients

Recombitek C8 - 47K9.R0

Administration Routes

SubcutaneousUnknownOral

Species Affected

Dog 206

Most Affected Breeds

Retriever - Labrador 16
Shih Tzu 15
Retriever - Golden 14
Chihuahua 10
Shepherd Dog - Australian 9
Pit Bull 9
Dachshund (unspecified) 9
Shepherd Dog - German 9
Spaniel - King Charles Cavalier 7
Terrier - Yorkshire 7

Most Reported Reactions

Vomiting 49
Injection site pain 34
Diarrhoea 23
Injection site swelling 22
Lethargy (see also Central nervous system depression in 'Neurological') 22
Lethargy (see also Central nervous system depression in Neurological) 21
Injection site lump 20
Anorexia 15
Seizure NOS 14
Pain NOS 13
Death 12
Lack of efficacy (virus) - parvovirus (including feline panleukopenia) 11

Outcome Breakdown

Outcome Unknown
88 (42.5%)
Recovered/Normal
80 (38.6%)
Ongoing
20 (9.7%)
Died
12 (5.8%)
Euthanized
7 (3.4%)

Recombitek C8 - 47K9.R0 Adverse Event Insights

206 reports name Recombitek C8 - 47K9.R0; 19 recorded a death outcome (9.2% of reported events, not a population-level mortality rate). Active ingredient: Recombitek C8 - 47K9.R0. Administration routes: Subcutaneous, Unknown, Oral.

By species: Dog (206 reports). By breed: Retriever - Labrador (16), Shih Tzu (15), Retriever - Golden (14).

Leading clinical signs: Vomiting (49), Injection site pain (34), Diarrhoea (23), Injection site swelling (22). Outcome, 207 coded reports: Outcome Unknown leads at 42.5%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.